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Objective: To evaluate if patterned electroceutical dressing (PED) is safe for
human chronic wounds treatment as reported by wound care providers.
Approach: This work reports a pilot feasibility study with the primary objec-
tive to determine physically observable effects of PED application on host
tissue response from a safety evaluation point of view. For this pilot study,
patients receiving a lower extremity amputation with at least one open wound
on the part to be amputated were enrolled. Patients were identified through
the Ohio State University Wexner Medical Center (OSUWMC) based on in-
clusion and exclusion criteria through prescreening through the Comprehen-
sive Wound Center’s (CWC) Limb Preservation Program and wound
physicians and/or providers at OSUWMC. Wounds were treated with the PED
before amputation surgery.
Results: The intent of the study was to identify if PED was safe for clinical
application based on visual observations of adverse or lack of adverse events
on skin and wound tissue. The pilot testing performed on a small cohort (N =8)
of patients showed that with engineered voltage regulation of current flow to
the open wound, the PED can be used with little to no visually observable
adverse effects on chronic human skin wounds.
Innovation: The PED was developed as a second-generation tunable electro-
ceutical wound care dressing, which could potentially be used to treat wounds
with deeper infections compared with current state of the art that treats
wounds with treatment zone limited to the surface near topical application.
Conclusion: Technology advances in design and fabrication of electroceutical
dressings were leveraged to develop a tunable laboratory prototype that could
be used as a disposable low-cost electroceutical wound care dressing on chronic
wounds. Design revisions of PED-1 (1 kO ballast resistor) circumvented pre-
viously observed adverse effects on the skin in the vicinity of an open wound.
PED-10 (including a 10 kO ballast resistor) was well tolerated in the small
cohort of patients (N= 8) on whom it was tested, and the observations reported
here warrant a larger study to determine the clinical impact on human wound
healing and infection control.
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INTRODUCTION
In the United States, 6.5 million patients are
affected by chronic wounds adding an estimated
US$25 billion annually to health care costs.1 A re-
cent meta-analysis of 9 chronic wound studies in-
volving 185 wounds reported >75% prevalence of
biofilms in chronic wounds.2 In addition to im-
paired cellular wound healing processes, the pres-
ence of biofilm infection derails natural wound
healing.3–14 Innovative strategies to combat wound
biofilm infection, while promoting healing of hard-
to-heal wounds, are urgently needed.
The human skin has an intrinsic transepithelial
potential (TEP) generated and maintained by ion
flow.15 After injury, when the skin continuity is
disrupted, a wound electrical current (EC) is mo-
mentarily generated followed by establishment of a
lateral electric field (EF).16–19 There is growing
research to suggest that this transverse EF pro-
motes wound healing by stimulating the (1) mi-
gration of neutrophils and macrophages,20,21 (2)
activity of fibroblasts,22 and (3) blood flow.23–30 In
the United States, electrical stimulation (ES) de-
vices have been used for the treatment of chronic
wounds since 2002.19,31,32 Such treatment has also
been reimbursed by Medicare in wounds that have
failed to heal using standard wound therapies.32
Multiple clinical studies have demonstrated that
ES together with standard of care (SoC) is more
effective than SoC alone.19
The concept of smart electrical bandages is
slowly gaining momentum33–37; the idea of pro-
viding engineered, controllable EC and EF through
disposable low-cost electroceutical wound care
dressing is innovative and not currently available.
The first-generation technology, a wireless elec-
troceutical dressing (WED), is available commer-
cially (Procellera) with FDA clearance for burn
care dressings.38–42 This textile-based dressing is
wireless and does not need any external power
supply, making it well suited for application as
disposable antimicrobial wound care dressing. We
reported that EF generated by the WED due to the
silver-zinc (Ag/Zn) redox chemistry is effective as
prohealing38 and antibiofilm.39,40
We have recently developed the next-generation
disposable dressing (patterned electroceutical
dressing or PED) that can deliver controlled EC to
wounds. Notably, the PED operates with a constant
input voltage source, currently provided by a 6V
battery, making it an active dressing as opposed to
theWED,which is a passive dressing. Based on our
unpublished in vitro and preclinical porcine biofilm
infection data on burn wounds, we designed a clini-
cal study to test PED in human chronic wounds. To
test clinical prototype design viability, we devel-
oped an in vitro biofilm assay.43 Followingmultiple
iterations of designs to evaluate size, spacing, im-
pact of electrode geometry patterns, we observed
that maximal biofilm inhibition was observed on
the anode.43 Based on this observation, a novel in-
terdigitated electrode patternwith a broader anode
interwoven with a narrower cathode (Fig. 1) was
developed for the clinical prototype. The purpose
behind this choice of designwas to provideminimal
internal resistance to flow of electric current as it
flows from anode to cathode while providing high
contact area for the anode with respect to the open
woundarea. PED treatmentwas applied to infected
porcine wounds for 14 days with intermittent dress-
ing changes. Importantly, initial host response of
wound repair (epithelialization and granulation
tissue) to PED was noted to be not impaired, es-
tablishing that the treatment was safe for host tis-
sue. These results prompted this study, which was
Figure 1. PED clinical prototype. (A) Schematic for PED is shown. The
electroceutical dressing consists of an interdigitated silver ink pattern on
silk fabric; the dressing is powered by a 6 V battery (B) (Model No. 36-3025-
2-ND) with a 10 kO resistor (R) that limits the current in the active circuit.
GND, ground; SW, switch (Model No. 563-1151-ND). (B) Fully assembled
PED-10 for clinical use. PED, patterned electroceutical dressing; PED-10,
dressing with 10 kO ballast resistor.
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designed as a feasibility study with the primary
objective to determine if PED treatment for human
chronic wounds is safe to use in a clinical setting
based on visual reporting by wound care providers
on the lack of adverse events (AEs) after treatment
with PED.
CLINICAL PROBLEM ADDRESSED
Chronic wounds are an ongoing challenge for cli-
nicians anda seriouspublic health burdendue to the
high cost of care of the ulcers themselves and pos-
tulceration complications such as amputations. The
identification of an alternate effective therapy to
either complement SoC or work independently than
the current SoC, promoting wound healing while
being safe for application, is a key clinical need.
ES as wound therapy is not a new technology,
and has been supported by numerous preclinical
and clinical studies. However, the lack of clearly
defined, standardized methods for using the
available electrical devices has limited their wide-
spread application in the wound care arena.
Moreover, a priority with using such devices is to
ensure that it is safe for use on the human skin.
MATERIALS AND METHODS
PED Design and Quality Control
The clinical PED prototype reported in this ar-
ticle (Fig. 1) was engineered through an iterative
design process with significant in vitro experi-
ments.44 The clinic-ready PED prototypes were
mass produced by professional engineering staff at
the Center for Design and Manufacturing Ex-
cellence (CDME) at The Ohio State University
(OSU) using highly specific medical-grade silk
material, silver ink, and medical tape backing. The
concept, design, laboratory-scale development, and
initial testing of the laboratory-scale prototypes,
including simplified setups to evaluate mecha-
nisms of operation for the PED, have been reported
previously44 (and unpublished observations: Stood-
ley P, The Ohio State University; Prakash S, The
Ohio State University). The circuit and batteries
attached to the dressing were encased in a fluid-
resistant injection molded encasing. For insulating
patients fromelectrical exposure, the circuit includes
a ballast resistor connected in series with the battery
to limit current below the approved FDA standards
(in compliance with IEC 60601). The first version of
clinical PED named as dressing with 1 kO ballast
resistor (PED-1) included a 1 kO ballast resistor,
the subsequent version was named as dressing with
10 kO ballast resistor (PED-10) and comprises a
10 kO ballast resistor to reduce the amount of cur-
rent towounds comparedwith the 1kOdressing, and
scaled by Ohm’s law.44 These dressings were steril-
ized at a commercial sterilization facility. All sterile
units of PED-10 were individually packed and iden-
tified using a unique serial number ID. As part of
quality control (QC), each unitwas individually tested
electrically before sterilization by CDME staff to meet
the specification of delivering £0.6mA to the wound.
Biological QC of PED: in vitro agar biofilm as-
say. Weutilized an in vitro agar biofilm assay45 to
test the biological activity of clinical PED. To per-
form biological QC of every lot of the CDME man-
ufactured PED, 5% of the dressings were randomly
selected and subjected to an agar Pseudomonas
aeruginosa (PA) biofilm assay (Fig. 2A). This bac-
terium is a known pathogen in wound infec-
tions,2,3,6–8,10,12,39,40,46 and has been previously
used as a model organism to test antibiofilm effects
of electroceuticals and other treatments.39,40,47 The
strain of Pseudomonas used for this assay is a bio-
luminescent strain of P. aeruginosa (Xen41; base
strain PA01; PerkinElmer).6,39,40 This strain con-
tains an integrated plasmid carrying a luciferase
gene that is constitutively expressed. P. aeruginosa
strains were cultured in low-salt Luria broth (LB)
for planktonic culture and the respective agar for-
mats for biofilm studies (Thermo Fisher Scientific).
Bioluminescent bacteria only produce light when
they are metabolically active. Thus, we used light
emission as detected with the in vivo imaging sys-
tem (IVIS) spectrum system (PerkinElmer), as an
indicator of bacterial activity.47
Static biofilms were developed in vitro using an
agar biofilm model and Xen41. Grown overnight in
LB media at 37C, bacteria were cultured on LB
agar plates, and allowed to form a mature biofilm
for 48h (Fig. 2A). The bioluminescence imaging
confirmed presence of a thick biofilm (Fig. 2B). In-
terestingly, PA biofilms could not be grown on the
agar directly formed on top of the PED. Therefore,
agar sections containing mature biofilms were
transferred to a new culture plate, and placed ei-
ther directly on the plate (control 1: no dressing,
Fig. 2C) or on a PED placed in the agar plate
(Fig. 2C). All dressings were connected to batteries
that were turned either OFF (control 2, Fig. 2D) or
ON (test, Fig. 2D). Agar biofilms with treatments
were incubated at 37C for 24h in a moist envi-
ronment to prevent dehydration of the agar sec-
tions. After incubation, agar sections with biofilms
were subject to IVIS imaging.
Clinical study: human subjects and study design.
This study was designed as a pilot feasibility
study with the primary objective to determine
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effects of PED application on host tissue response
from a safety evaluation point of view. The study
was approved by the OSU Institutional Review
Board (IRB 2015H0408). The Declarations of
Helsinki protocols were followed, and the patients
gave their written informed consent. For this pilot
study, patients receiving a lower extremity am-
putation with at least one open wound on the part
to be amputated were enrolled. Our treatment
was not with the intent of limb salvage but to de-
termine safety and experience of PED use in the
clinic. Patients were identified and enrolled through
Figure 2. Biological testing of clinical PED-10 using agar biofilm bioluminescent assay. (A) Forty-eight-hour mature Pseudomonas aeruginosa (PA Xen41)
biofilms on agar strips were placed on culture plates with or without PED-10. The experiment setup of the agar biofilm bioluminescence assay for clinical PED
biological testing. Top panels show the appearance of the agar biofilms 48 h postinoculation with Xen41. (B) Agar lawn biofilms were confirmed using IVIS
imaging for metabolic activity, followed by excising strips of agar containing mature biofilm from plated. Bottom panels show the excised strips that were
tested again for metabolic activity of biofilm by IVIS imaging before transfer onto control or test plates. (C) Plates (n = 3 agar slices/plate) included control 1 (no
dressing), control 2 (PED-battery OFF), and test (PED-battery ON). (D) Representative digital and corresponding IVIS image of Xen41 exposed to controls or test
treatment. Also included is a heat map showing intensity ranges. The intensity of blue signal shows that bacteria in both control groups show detectable
metabolic activity, whereas the test group (battery ON) showed no activity indicating absence of viable bacteria. IVIS, in vivo imaging system.
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the Ohio State University Wexner Medical Cen-
ter (OSUWMC). The patients were selected based
on inclusion and exclusion criteria through pre-
screening (partial HIPAA wavier) through the
Comprehensive Wound Center’s (CWC) Limb
Preservation Program and wound physicians/
providers at OSUWMC. The decision of whether
to amputate was made independently of the study,
and was solely made by the patients and their
physician/provider. The provider decides based on
the severity of the condition if or when the limb
should be amputated and scheduled the surgery
based on current clinical SoC. Patients enrolled
in the study wore the PED on the wound(s) for a
minimum of 24h or a maximum of 3 weeks or until
amputation, whichever came first. Patients were
consented on their first visit to the CWC. The pa-
tients were instructed to change the PED every
second day or more frequently if excessive drainage
was observed as advised by the treating physician
and/or medical provider. Patients were advised to
report any adverse indications visually observed
during the dressing changes. Observation of any
adverse indications was corroborated by the at-
tending physician, and detailed reports were filed
per IRB requirements. PED risks: the use of the
current limiter served as a fail-safemechanism, and
eliminated the possibility of excessive and uncon-
trolled current flow into the wound area. Thermal
imaging confirmed that the heat generated by PED
is minimal and negligible as determined by negli-
gible temperature rise across the agar gel plates.44
RESULTS
PED Clinical Prototype Fabrication and Design
The PED comprises a biocompatible and com-
mercially available silk fabric, medical-grade Ag/
AgCl ink, and a waterproof medical tape backing
(Fig. 1). The power source includes a 1 kO (PED-1)
or 10 kO (PED-10) resistor to limit current flow, an
ON/OFF switch, and a battery (6V) with positive
and negative leads that attach to the dressing, all
enclosed in an epoxy resin molded waterproof cas-
ing to minimize direct contact of the active electric
circuit componentswith thewoundfluid. The power
source for the PED, that is, 6V batteries, is com-
parable with smaller devices using 9V batteries
that are approved by the FDA for human use, such
as the TENS 7000 pain management unit. In ad-
dition,manual control elements have been included
in the PED design to limit current flow, which al-
lows nominal estimates based on the geometric area
of the electrodes, and to permit deposition of power
density to tissue within FDA limits. The estimates
for power density were conducted by the CDME
staff by corresponding current flow measurements
in saline. The manual control features include (1)
an ON/OFF switch for the patient to switch off the
device in case of perceived or felt discomfort—none
of the N=8 patients reported any discomfort with
the application of powered ON PED; (2) a ballast
resistor, connected in series between the positive
lead of the battery and the positive lead of the
dressing to limit current flow through the dressing.
The maximum power density measured with this
electroceutical wound care dressing and the 6V
batterywas 60.3lW/cm2 at the anode and 753.6lW/
cm2 at the cathode, well below the FDA power
density limit (0.25W/cm2)44 withmeasurements on
an agar gel plate without a bacterial lawn. The
calculations took the nominal, geometric conduc-
tive surface area, maximum current measured
under steady current flow conditions, and voltage
from the power source into consideration during
in vitro measurements. The maximum power den-
sity was based on the maximum current measured
from a dressing coated with hydrogel, as used with
pig models and consented patients (Fig. 1).
The last PED applied to the patient during the
feasibility study protocol and subsequently taken
off in the operating room (OR) was checked for
voltage and current flow levels using a multimeter
(Amprobe 34XR-A True-rms Digital Multimeter).
Results from patients postapplication for five of the
eight dressings tested are presented in Table 1.
Before use on the subject’s wound, unused PED-10
exhibited a consistently stable voltage of 6.4V and
maximum current of 600lA. The measurements
performed on the used dressings indicated that no
stable voltage or current could be detected post-
application. The study did not monitor the compli-
ance of the subject for changing dressing every 48h.
Table 1. Testing of electrical activity/parameters of PED-10
before and after clinical application
Subject ID
Anode to Cathode
Resistance (MU)
Voltage Across
PED (V)
Current Through
PED (lA)
PRE POST PRE POST PRE POST
PED 004 open (>40) Open (>40) 6.44 0 600 0.0
PED 005 open (>40) Open (>40) 6.48 2.85 607 0.0
PED 006 open (>40) Open (>40) 6.43 0 607 0.0
PED 007 open (>40) Open (>40) 6.44 0 605 0.2
PED 008 open (>40) Open (>40) 6.45 0 607 0.2
Electrical parameters such as resistance between electrodes, voltage,
and current across the dressing were measured using a multimeter. ‘‘PRE’’
values represent measurements before application on subject wounds.
‘‘POST’’ values represent readings that were taken after dressing removal
from subject wounds.
PED, patterned electroceutical dressing; PED-10, dressing with 10 kO
ballast resistor; POST, postapplication; PRE, preapplication.
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None of the patients reported any physical discom-
fort, pain, or irritation post-PED-10 application.
PED Inhibits Biofilm Formation In Vitro
An agar biofilm assay45 was utilized to test the
biological efficacy of PED against biofilm growth
in vitro (Fig. 2A). Preformed (48h) biofilm treated
with PED-10 with battery turned ON resulted in
partial loss of bioluminescence signal as imaged
using IVIS. This loss of signal is indicative of in-
hibition in the metabolic activity of PA biofilm, and
was confirmed bymonitoring colony-forming units.
Such inhibition was not evident in the absence of
an active EC (control 2 or no PED treated control 1,
Fig. 2B). As a standard QC criterion, from every lot
of CDME-fabricated PED-10, the biological test is
performed on 5% from a lot of 100 of the dressings
(based on random selection) to confirm the biolog-
ical efficacy of the fabricated dressings.
Pilot Clinical Testing with PED-10 Indicated
Safe Application for Chronic Wound Use
Demographics and wound etiologies of eight
enrolled subjects in the study are presented in
Table 2. Subjects were all diagnosed with chronic
nonhealing wounds that required amputation. The
primary objective of this study was not to save the
lower extremity part or determine PED efficacy but
to determine if PED application could be poten-
tially safe for chronic wound use as reported by the
patients based on their personal level of comfort
and/or visual changes to the wound environment.
Of the eight subjects enrolled, only PED001 was
treated with PED-1 (with the 1 kO ballast resistor).
During the first dressing change 48h postinitial
treatment, the patient’s care provider noted skin
irritations and some skin discoloration that was
photodocumented, and reported to the study team
including the physician immediately (Fig. 3). The
event was deemed as an AE that was anticipated
and reported as a nonserious AE to IRB. At that
point, the study team met and decided to limit the
amount of current delivered to the wound by in-
Table 2. Subject demographics and wound etiology
Subject ID Age Gender Race Smoker Diabetes Wound Location Days of PED Use Amputation Cause
PED001 43 Male Caucasian N Yes Right foot 2 Charcot foot
PED002 62 Female Caucasian N Yes Right foot 4 Uncontrolled infection
PED003 59 Female African American N Yes Left foot 10 Osteomyelitis
PED004 52 Male Caucasian N Yes Left foot 8 Osteomyelitis
PED005 63 Male Caucasian N Yes Toe and left plantar 10 Osteomyelitis
PED006 62 Male Caucasian N Yes Right great toe 18 Great toe ulceration with concern
for osteomyelitis
PED007 51 Male Caucasian Y Yes Left heel 21 Bone infection
PED008 59 Male Caucasian Y Yes Right plantar 1 Chronic osteo/Charcot foot
Figure 3. Mild AEs associated with clinical PED-1 treatment application.
(A) The first subject with PED-1 application reported AE associated with the
PED treatment. This report described that during the first dressing change,
the nurse noted a skin discoloration and minor irritation in skin surrounding
the ulcer that was documented in the attached photograph (right). The
treatment of PED-1 was immediately discontinued, and the event reported to
IRB as unanticipated nonserious AE. At this stage, the study was put on a
hold, and clinical PED was redesigned to replace 1 kO with 10 kO ballast
resistor to reduce current to wounds and surrounding tissue. This PED was
named as PED-10. Subsequently all subjects received PED-10. (B) Re-
presentative image of a wound treated with PED-10. AEs, adverse events;
IRB, Institutional Review Board; PED-1, dressing with 1 kO ballast resistor.
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creasing the electrical resistance in the circuit by
changing the ballast to 10 kO (PED-10). All sub-
sequent subjects were treated with PED-10, and no
further similar AE were noted or reported. In one
other case (PED006), a minor discoloration of the
area of application at the amputation visit was
noted and was deemed by the study physician as a
standard response to silver dressings, and there-
fore no changes to the PED-10 or testing protocols
were made. The photographs of the wounds before
and immediately after the application of the first
PED at clinic are also presented (Fig. 4). Any other
images of the wound could not be obtained because
of challenges in obtaining images within the OR.
For PED001, the PED-1 dressing was used, and for
all other subjects the PED-10 dressing was used.
DISCUSSION
Bacterial biofilms are complex aggregations of
bacteria and extrapolymeric substances.3,46,48 The
composition and organization of biofilms and their
inherent resistance to antibiotics and host immune
cells make these structures particularly challeng-
ing to treat.4,5,49–51 The prevalence of biofilm in-
fection in chronic wounds is exceedingly high
(>75%).2 Several studies, including those from our
own laboratories, have indicated that biofilm infec-
tions impair wound healing.2,6–8,10,11,13,14 There-
fore, novel strategies of dismantling biofilms are a
primary and immediate need in wound care.
ES therapy of chronic wounds has emerged as a
viable therapeutic option nationally and interna-
tionally.52 In the United States, since 2002, ES has
been reimbursed by Medicare in the context of
nonhealing leg ulcers and pressure ulcers.32 The
rationale for ES use arises from the existence of an
intrinsic TEP that promotes the migration of neu-
trophils and macrophages, stimulates fibroblasts,
and improves blood flow.23,25–30 The strength of
EFs present during normal wound healing varies
throughout the healing process—starting high and
dissipating at the end of the healing process.25 The
majority of studies found that ES stimulated the
Figure 4. Clinical studies with PED. Digital images of wounds of all consented subjects before and immediately after the PED dressing application in clinic
were obtained. The subjects did not come back to CWC until their amputation visit. (A) Wounds treated with PED-1 (1 kO ballast resistor). (B) Wounds treated
with PED-10 (10 kO ballast resistor). CWC, Comprehensive Wound Center.
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efficacy of antibiotics against the biofilms.51,53–56
Among the earliest methods that showed great
promise against biofilms included those that utilized
either direct or alternating current with or without
antibiotics.51,53–61 The term ‘‘bioelectric effect (BE)’’
was specifically used in the context of EC enhancing
antibiotic efficacy.51,54,56 Details of the fundamental
mechanisms of the BE or treatments using EC alone
are still unclear, and could be attributed to diversity
in applied electrical parameters and methods for
treatment purposes5,33,51,53–57,59–67 and no stan-
dardized approach to conduct clinical evaluations.
Low-intensity direct current (LIDC) and high-
voltage pulse current (HVPC) have both been used
to demonstrate antimicrobial effect. Our laboratory
initially showed P. aeruginosa biofilm disruption
in vitro using WED, which generates weak EFs.
Recently, we published preclinical porcine studies
showing the efficacy of WED in treating biofilm-
infectedwounds.38–40 In this study, PED embedded
in agar inhibited initial establishment of biofilm
(data not shown) likely because of the release of
the silver from the dressing that inhibited/killed
planktonic bacteria,43 therefore to study the effects
of PED on biofilm disruption, mature biofilms were
first allowed to develop followed by placing the agar
pieces containingmature biofilm onPED.Although
PED inhibited metabolic activity of the P. aerugi-
nosa biofilm identified using IVIS imaging, this
study does not address if the effect was due to
bactericidal or static effects.
The effects of electrical therapy such as LIDC are
thought to be antibacterial due to (1) changes in pH
conditions near the electrode capable of killing
pathogens68,69; (2) electrolytic generation of toxic
compounds (H2O2 and chlorinated species such as
HOCl)70 (andunpublished observations: Stoodley P,
The Ohio State University); (3) disruption of bacte-
rial cell division71; (4) overstimulation of cell mem-
branes due to ion excitation leading to leakage72 and
in some cases; and (5) interferingwith adhesion and
cohesion of biofilm structures resulting in a plank-
tonic phenotype.63 Similar observations have been
made with HVPC treatments.69,73–75
PED has been developed with the intent of pro-
viding a disposable device that can provide con-
trolled EC to wounds to achieve elimination of
biofilm infection. The differences in battery usage
by wounds in different patients noted in this study
are likely due to differences in electrical resis-
tances in these wounds. Future studies mapping
current and field in chronic wounds may help in-
form the frequency of PED-10 dressing change to
obtain maximal efficacy against wound biofilm in-
fection. In this feasibility study, the EC was ad-
justed based on AE reported by the first subject
treated with PED-1. None of the other seven sub-
jects on whom PED-10 was used reported any sig-
nificant AEs, suggesting that PED-10 was well
tolerated and was deemed safe for use in a larger
clinical study based on visual observations of the
local wound area where the efficacy of this dress-
ing against chronic wound biofilm infection can be
explored.
INNOVATION
We developed a novel electroceutical treatment
for clinical wound biofilm infection that was tested
for topical application as determined by patient
physical sensation and visual changes in the region
on and around chronic human wounds. While the
concept of electrically active bandages is gaining
momentum, the idea of providing controlled electric
current through disposable electroceutical wound
care dressings is innovative and not currently
available. The PED reported here presents a plat-
form that is tunable for current control, and can
likely be readily adapted to unique wound and
patient needs. The ability to dial up or down the
current output of PED for a given, constant electric
potential with minimal physically observable AEs
under topical use on open chronic wounds is an in-
novation of the device. The pilot study as reported
here demonstrated the ability to apply the device on
human wounds.
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KEY FINDINGS
 PED is an electroceutical wound care dressing that can be tuned to
minimize AEs on chronic wounds.
 PED-10 is a disposable device that provides low-level electric current to
wounds.
 Pilot feasibility studies enabled the determination of appropriate dose of
electric current to mitigate observed adverse side effects.
 PED-10 was well tolerated in the small cohort of patients (7) tested, and
these observations warrant a larger study to determine impact on wound
healing and infection control.
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ABBREVIATIONS AND
ACRONYMS
AE ¼ adverse event
CDME ¼ Center for Design and
Manufacturing Excellence
CWC ¼ Comprehensive Wound Center
EC ¼ electrical current
EF ¼ electric field
ES ¼ electrical stimulation
HVPC ¼ high-voltage pulse current
IRB ¼ Institutional Review Board
IUH ¼ Indiana University Health
IVIS ¼ in vivo imaging system
LB ¼ Luria-Bertani
LIDC ¼ low-intensity direct current
MAE ¼ Mechanical and Aerospace
Engineering
OR ¼ operating room
OSUWMC ¼ The Ohio State University
Wexner Medical Center
PED ¼ patterned electroceutical
dressing
PED-1 ¼ dressing with 1 kO ballast
resistor
PED-10 ¼ dressing with 10 kO ballast
resistor
QC ¼ quality control
SoC ¼ standard of care
TEP ¼ transepithelial potential
WED ¼ wireless electroceutical dressing
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